Search
CX501
go.drugbank.com/drugs/DB05174InvestigationalCx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of … It is developed by Cellerix and is in phase I of clinical trials.
DG051
go.drugbank.com/drugs/DB05177ExperimentalDG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.
SQ-109
go.drugbank.com/drugs/DB05186InvestigationalCurrently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSynonyms: N-adamantanyl-N'-geranyl-ethylenediamineAtl146e
go.drugbank.com/drugs/DB05191InvestigationalATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.
Categories: Adenosine A receptor agonists, Heterocyclic Compounds, 2-RingMB07811
go.drugbank.com/drugs/DB05192InvestigationalMB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. … MB07811 combines a novel thyroid hormone receptor agonist with the Company's novel HepDirect liver targeting prodrug technology.
Ordopidine
go.drugbank.com/drugs/DB05196InvestigationalACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
CYC116
go.drugbank.com/drugs/DB05198InvestigationalCYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. … Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition
Categories: Heterocyclic Compounds, 1-RingLX1031
go.drugbank.com/drugs/DB05199InvestigationalLX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels.
AT2220
go.drugbank.com/drugs/DB05200InvestigationalIt is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of α-glucosidase (GAA). … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.